Abstract
Borderline ovarian tumors (BOT) have invited controversy for decades. In the last couple of years research has showed a shift towards less aggressive treatment. This review summarizes the latest studies and therapeutic consequences thereof. Staging procedures are recommended in the setting of serous BOT, but controversial in the setting of mucinous BOT, where they may represent overtreatment. Surgical staging is limited to bilateral salpingo-oophorectomy, peritoneal cytology/biopsies and an omentecomy. Neither a hysterectomy nor lymphadenectomy should be undertaken. Conservative management should consist of a cystectomy or unilateral salpingo-oophrectomy in the setting of serous BOT and unilateral salpingo-oophrectomy in the case of mucinous BOT. Bilateral disease should be treated by bilateral cystectomy whenever possible. At present, there are no data to support the use of adjuvant treatment in any setting of BOT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
